In a recent video interview, Raymond Y. Kwong, MD, discussed his clinical experience with the Vista.ai (formerly HeartVista) One Click MRI software and recent research, presented at the Radiological Society of North America (RSNA) conference, that revealed a 31 percent decrease in cardiac MRI scan times for patients with cardiomyopathy or structural heart disease.
For Raymond Y. Kwong, MD, MPH, FACC, FSCMR, long scan times with cardiac magnetic resonance imaging (MRI) can have a significant downstream effect on patient access to this technology. He noted the increased demand for cardiac MRI has led to wait times of three to five weeks for outpatients and four to five days for in-patients to be scheduled for a cardiac MRI.
“These numbers are really unacceptable for patient care from our standpoint,” noted Dr. Kwong, the director of Cardiac Magnetic Resonance Imaging in the Cardiovascular Division of the Department of Medicine at Brigham and Women’s Hospital in Boston, and a professor medicine at Harvard Medical School.
With this in mind, Dr. Kwong recently started using Vista.ai (formerly HeartVista) One-Click MRI, an artificial intelligence (AI)-enabled software that helps improve image quality as well as the efficiency of cardiac MRI procedures. At the recent Radiological Society of North America (RSNA) conference, Dr. Kwong shared his six-month experience with Vista.ai’s One-Click MRI and noted a 31 percent reduction in scan times based on 1,100 consecutive cardiac MRI studies performed between April 2022 and September 2022 for patients with cardiomyopathy or structural heart disease.
When employing full use of the Vista.ai One-Click MRI software, Dr. Kwong found that 90 percent of cardiac MRI studies could be completed in less than 45 minutes in comparison to 25 percent of non-AI-aided studies.
(Editor’s note: This interview was recorded prior to HeartVista’s announcement about the company name change to Vista.ai.)
For more insights from Dr. Kwong, watch the video below.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.